Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Operating Margin (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Operating Margin data on record, last reported at 7160.0% in Q3 2025.

  • For Q3 2025, Operating Margin fell 301406.0% year-over-year to 7160.0%; the TTM value through Sep 2025 reached 6927.32%, down 297049.0%, while the annual FY2024 figure was 4812.45%, 193936.0% down from the prior year.
  • Operating Margin reached 7160.0% in Q3 2025 per NWBO's latest filing, up from 11281.68% in the prior quarter.
  • Across five years, Operating Margin topped out at 1473.18% in Q1 2023 and bottomed at 11281.68% in Q2 2025.
  • Average Operating Margin over 5 years is 5205.0%, with a median of 4423.27% recorded in 2022.
  • Peak YoY movement for Operating Margin: skyrocketed 513965bps in 2022, then crashed -785737bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 2982.45% in 2021, then fell by -2bps to 3044.89% in 2022, then decreased by -12bps to 3402.7% in 2023, then plummeted by -135bps to 8008.23% in 2024, then rose by 11bps to 7160.0% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 7160.0% in Q3 2025, 11281.68% in Q2 2025, and 4616.27% in Q1 2025.